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Osteoporosis is characterized by low bone
mass and microarchitectural deterioration of
the skeleton, leading to fragility and increased
risk of fractures (Consensus Development
Conference 1993). Sweden is among the coun-
tries with the highest incidence of osteoporotic
fractures (Ismail et al. 2002; Kanis et al. 2002),
but established risk factors cannot fully explain
the wide geographic differences and the
increased incidence over time. Identiﬁcation of
risk factors is vital to prevent reduction of life
quality and life expectancy and to minimize
the high costs of treatment associated with the
disease. Known predictors of low bone mass
are older age, female sex, family history of
osteoporosis, early menopause, physical inac-
tivity, low body weight, low intake of calcium
and vitamin D, smoking, and alcohol con-
sumption (Genant et al. 1999; National
Institutes of Health Consensus Development
Panel on Osteoporosis Prevention, Diagnosis,
and Therapy 2001).
The toxic effect of cadmium on bone
became evident at the outbreak of Itai-itai dis-
ease in Japan, where severe renal and skeletal
damage in women was associated with con-
sumption of heavily cadmium-polluted rice
(Kjellström 1992). Cadmium is a widespread
environmental pollutant, present in food
(mainly cereals, vegetables, and shellﬁsh) and
tobacco. It poses a threat to human health
because of its long retention (decades) in the
kidneys (Järup et al. 1998). Recent studies
indicate that relatively low exposure may also
affect the skeleton (Alfvén et al. 2004; Staessen
et al. 1999), but the relationship is not well
documented. Whether the effects are mediated
directly on bone or are secondary to kidney
damage is still unclear (Kjellström 1992).
In contrast to cadmium, lead accumulates
in bone by the replacement of calcium, and
the skeleton contains as much as 90% of the
lead body burden (Berglund et al. 2000;
Nilsson et al. 1991).
The aim of this study was to assess associa-
tions between cadmium retention and bone
effects in women of upper middle age, the
most susceptible part of the population, with
regard to both cadmium retention (Nishijo
et al. 2004) and osteoporosis (Ismail et al.
2002; Kanis et al. 2002). We examined indica-
tors of bone status, reﬂecting both short-term
effects [markers of bone metabolism and
parathyroid hormone (PTH)] and long-term
effects [bone mineral density (BMD)]. We
addressed the question of whether the effects
of cadmium are mediated through kidney
damage. We also assessed the impact of bone
remodeling on endogenous lead exposure.
Materials and Methods
Study population. The Women’s Health in the
Lund Area (WHILA) study, a population-
based study of all women 50–59 years of age in
the community of Lund, in southern Sweden
(n = 10,766), started in December 1995
(Lidfeldt et al. 2001). In June 1999, when
1,160 subjects remained to be examined, the
study was extended to include health aspects of
cadmium and lead (Åkesson et al. 2005). The
participation rate was 71% (n = 820). The
exclusion criteria were hypo- and hyper-
parathyroidism (n = 4), rheumatoid arthritis
(n = 7), or oral use of corticosteroid drugs
(n = 6). We collected data on lifetime smok-
ing, alcohol consumption, physical activity,
and reproductive factors, including hormone
replacement therapy (HRT), via a question-
naire. Body weight and height were measured.
We obtained morning spot urine from
797 women and blood from 727 women. All
samples were collected during 8 months from
June 1999 through January 2000. The ethics
committee at Lund University approved the
WHILA study, and oral informed consent was
obtained from each participant.
Measurements. Exposure assessment was
based on cadmium in blood as a measure of
ongoing exposure (which we assume has been
fairly constant over time) and cadmium in
urine as a measure of body burden (cadmium
in urine correlates well with cadmium in the
kidney cortex; Järup et al. 1998; Orlowski
et al. 1998). In addition, we measured lead in
blood (indicator of exposure). All equipment
used in the study was tested, and possible con-
tamination was below the limit of detection
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High cadmium exposure is known to cause bone damage, but the association between low-level
cadmium exposure and osteoporosis remains to be clarified. Using a population-based women’s
health survey in southern Sweden [Women’s Health in the Lund Area (WHILA)] with no known
historical cadmium contamination, we investigated cadmium-related effects on bone in 820 women
(53–64 years of age). We measured cadmium in blood and urine and lead in blood, an array of
markers of bone metabolism, and forearm bone mineral density (BMD). Associations were evalu-
ated in multiple linear regression analysis including information on the possible confounders or
effect modiﬁers: weight, menopausal status, use of hormone replacement therapy, age at menarche,
alcohol consumption, smoking history, and physical activity. Median urinary cadmium was
0.52 µg/L adjusted to density (0.67 µg/g creatinine). After multivariate adjustment, BMD, para-
thyroid hormone, and urinary deoxypyridinoline (U-DPD) were adversely associated with concen-
trations of urinary cadmium (p < 0.05) in all subjects. These associations persisted in the group of
never-smokers, which had the lowest cadmium exposure (mainly dietary). For U-DPD, there was a
signiﬁcant interaction between cadmium and menopause (p = 0.022). Our results suggest negative
effects of low-level cadmium exposure on bone, possibly exerted via increased bone resorption,
which seemed to be intensiﬁed after menopause. Based on the prevalence of osteoporosis and the
low level of exposure, the observed effects, although slight, should be considered as early signals of
potentially more adverse health effects. Key words: biochemical bone markers, bone mineral density,
cadmium, lead, osteoporosis, women. Environ Health Perspect 114:830–834 (2006).
doi:10.1289/ehp.8763 available via http://dx.doi.org/ [Online 2 February 2006](LOD). Blood cadmium [LOD = 0.12 μg/L;
precision = coefficient of variation (CV) =
7.4%], blood lead (LOD = 0.26 μg/L;
CV = 3.1%), urinary cadmium (LOD =
0.31 μg/L; CV = 8.5%), and urinary calcium
(LOD = 1.6 mg/L; CV = 6.4%) were deter-
mined by inductively coupled plasma mass
spectrometry (Barany et al. 1997). The ana-
lytical accuracy was good and is described in
detail elsewhere (Åkesson et al. 2005).
We measured the following biochemical
markers related to bone metabolism: PTH,
osteocalcin, and bone alkaline phosphatase
(bALP) in serum; and deoxypyridinoline
(U-DPD) and calcium in urine. We used
immunoassays to determine intact PTH
(Elecsys; Roche, Mannheim, Germany), osteo-
calcin (ELSA-Osteo; CIS Bio International,
Gif-Sur-Yvette Cedex, France), and U-DPD
(Immulite 2000 Pyrilinks-D; DPC, Los
Angeles, CA, USA) and immunoradiometric
assay to detect bALP (Tandem-R Ostase;
Beckman Coulter, Inc., Fullerton, CA, USA).
The CVs were < 4% for PTH, 10% for osteo-
calcin, < 9% for U-DPD, and < 11% for
bALP.
We measured BMD of the nondominant
wrist (at the 8 mm distal position) using dual-
energy X-ray absorptiometry (DXT 200;
Osteometer MediTech, Inc., Hawthorne, CA,
USA). We used a phantom for daily calibra-
tion of the instrument, and one technician
performed all measurements. The measured
BMD was automatically compared with a
“reference” population furnished by the
instrument supplier, giving T-scores, deﬁned
as (BMDo – BMDm)/SD, where BMDo is the
obtained BMD, BMDm is the mean value for
20-year-old Danish female controls, and SD is
the standard deviation in the same reference
population. Osteopenia was defined as
–2.5 < T-score < –1.0, and osteoporosis as
T-score < –2.5, according to the World Health
Organization (WHO), based on the measure-
ment of proximal femur (WHO 1994).
The kidney-effect markers measured were
estimated glomerular filtration rate (GFR),
creatinine clearance, and human-complex–
forming protein (protein HC), and N-acetyl-
β-D-glucosaminidase (U-NAG) in urine, as
described previously (Åkesson et al. 2005).
Because creatinine excretion is depen-
dent on muscle mass, which in turn may
predict BMD, we chose to adjust all urinary
markers to the group mean urinary density
(1.015 g/mL) instead of to urinary creatinine
(Åkesson et al. 2005; Suwazono et al. 2005).
Statistical analyses. Data from two inde-
pendent groups of subjects were compared by
the Mann-Whitney U-test. We used Spearman
rank correlation (rs) or Kendall’s tau to assess
univariate associations (p ≤ 0.1). In multiple
linear regression models, each bone-related
variable was evaluated in relation to cadmium,
potential confounders (factors associated with
both cadmium and bone) and effect modiﬁers
(factors associated with bone). We explored
possible interactions in the model. Because the
season of sampling correlated with blood and
urinary cadmium, BMD, PTH, U-DPD, and
urinary calcium, it was included in the models.
Residual and goodness-of-ﬁt analyses indicated
no deviation from a linear pattern in the
regression models. The ﬁnal regression model
included, apart from cadmium, only statisti-
cally signiﬁcant variables (p ≤ 0.05). All tests
were two sided, and statistical evaluation was
performed using SPSS (version 12.01; SPSS
Inc., Chicago, IL, USA).
Results
The main characteristics of the participants
are shown in Table 1. Current smokers had,
on average, cadmium concentrations three
times as high in blood (1.1 vs. 0.30 μg/L) and
1.5 times as high in urine (0.76 vs. 0.45 μg/L)
compared with never-smokers.
In a ﬁrst evaluation, we assessed the uni-
variate associations between cadmium and the
various bone-related variables and covariates
(Table 2). Urinary cadmium was negatively
associated with BMD (Table 2, Figure 1) and
PTH, and positively associated with bALP
and U-DPD (Table 2, Figure 2), but not with
osteocalcin or urinary calcium. Similar but
less pronounced associations were obtained
for blood cadmium. Physical activity, parity,
and total months of lactation were not associ-
ated with the bone-related variables.
Women on HRT had signiﬁcantly higher
BMD (p < 0.001) as well as lower osteocalcin,
bALP, U-DPD, blood lead (p < 0.001), and
urinary calcium (p < 0.023) than post-
menopausal women without HRT. There were
no differences in blood or urinary cadmium
between the two groups.
Multivariate analyses. In the multiple lin-
ear regression analyses, we evaluated further
the associations between cadmium and bone
by including potential confounders and effect
modifiers (e.g., smoking and body weight,
age, alcohol consumption, menopausal sta-
tus including HRT, and age at menarche)
(Table 3). We did not include blood lead as
an explanatory variable in the models, in spite
of the fact that it was associated with several
of the skeletal biomarkers and BMD, because
there is a known inverse relationship, that is,
that skeletal demineralization releases lead
into the blood. In the adjusted model, urinary
cadmium, but not blood cadmium, showed a
significant negative association (p = 0.047)
with BMD. In a separate analysis in never-
smokers with a lower cadmium exposure, the
corresponding result was β = –0.02 g/cm2 per
microgram per liter (p = 0.045; data not
shown). Based on the adjusted model, we cal-
culated the differences in BMD for the aver-
age woman with respect to age and weight at
different levels of exposure. The exposure cor-
responding to the 99th percentile of urinary
cadmium concentration had, on average,
5–6% lower BMD than those in the first
percentile. This magnitude of difference was
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Table 1. Participant characteristics and data on exposure and bone-related variables in a population-
based study of Swedish women.
Median (5th–95th percentiles) No. of samples
Population characteristics
Age (years) 58 (54–63) 804
Weight (kg) 69 (54–94)
Living alone or with children (%) 17
Education > 12 years (%) 27
Smokers: never/former/current (%)  55/24/22
Pack-years: former/current smokers 10 (1–36)/20 (4–42)
Alcohol consumption (grams ethanol/week) 20 (0–150)
Menarche (age) 13 (11–16)
Parity 2 (0–4)
Lactation (months) 6 (0–24)
Premenopausal/HRT/postmenopausal (%) 3/35/62
Exposure variables 
Blood cadmium (µg/L) 0.38 (0.16–1.8) 715
Urinary cadmium (µg/L)a 0.52 (0.24–1.3) 795
Blood lead (µg/L) 22 (11–46) 716
Bone-related variables 
BMD (g/cm2) 0.44 (0.33–0.54) 803
Osteopenia, –2.5 < T-score < –1.0 (%) 42
Osteoporosis, T-score < –2.5 (%) 7.2
PTH (ng/L) 28 (13–57) 719
Osteocalcin (µg/L) 19 (9–33) 719
bALP (µg/L) 12 (6–21) 645
U-DPD (nmol/L)a 46 (25–85) 794
Urinary calcium (mg/L)a 135 (57–265) 797
Data are presented as median (5–95% percentiles) except as noted.
aAdjusted to mean density of 1.015 g/mL.Åkesson et al.
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similar to that observed by a 6-year increase in
age or an 11-kg lower body weight.
Both blood and urinary cadmium were
negatively associated with PTH (Table 3);
this was true for urinary cadmium even after
excluding ever-smokers (β = –5.4 ng/L per
microgram per liter; p = 0.027; data not
shown). Urinary cadmium, but not blood
cadmium, displayed a near-signiﬁcant associa-
tion (p = 0.06) with bALP. Further, urinary
cadmium was associated with U-DPD
(Table 3), even in never-smokers (β = 16
nmol/L per microgram per liter; p < 0.001;
data not shown). The association between
U-DPD and urinary cadmium was more pro-
nounced (interaction term; p = 0.022) in post-
menopausal women (β = 21 nmol/L per
microgram per liter; Table 3) than in the HRT
group together with premenopausal women
(β = 12 nmol/L per microgram per liter).
In additional analyses, we evaluated the link
between the cadmium-associated bone markers
and the kidney effect markers. We included
each kidney-effect marker in the multiple lin-
ear regression models for BMD, PTH, and
U-DPD. Both urinary cadmium and U-NAG
were associated with PTH and U-DPD but
not with BMD. However, GFR and urinary
protein HC were not associated with any of
the cadmium-associated bone markers.
Blood lead was higher in the post-
menopausal women without HRT than in
the HRT group and was associated with all
bone parameters, except PTH (Table 2,
Figure 3). Potential confounders were smok-
ing and alcohol intake. Body weight and
HRT were also associated with both blood
lead and bone effects markers but are likely to
be steps on a causal route rather than con-
founders. When body weight and alcohol
were included in a multivariate model, signiﬁ-
cant associations with blood lead were still
present for osteocalcin, bALP, U-DPD, and
urinary calcium (all p-values ≤ 0.037).
However, when HRT was included, the asso-
ciations with blood lead became weaker
(bALP and urinary calcium were no longer
statistically significant, and the slopes
decreased for osteocalcin and U-DPD).
Discussion
This population-based study of upper-middle-
age women, representative of the general popu-
lation of southern Sweden, is the ﬁrst to report
assessment of a variety of biochemical bone
markers in relation to cadmium exposure. We
showed clear associations between increasing
cadmium body burden, on one hand, and
decreasing BMD, increasing bone resorption
(U-DPD), and decreasing PTH, on the other.
The associations persisted even in the group of
never-smokers, which had the lowest cadmium
exposure.
This study has several methodologic advan-
tages, including the large sample size and high
participation rate. Nevertheless, in health sur-
veys, there may be a selection such that subjects
with diseases, probably including those with
bone disorders, participate to a lesser or to a
greater extent than others. If fewer subjects with
diseases participate, we may underestimate the
risk of cadmium-induced bone damage; if more
of these subjects participate, it may affect the
generalizability of the results. However, the pre-
sent prevalence of osteoporosis agrees well with
the 7% value previously reported in Swedish
women of the same age (Ringertz et al. 1995).
Other advantages are the inclusion of several
different markers of bone effects and con-
founders, and the fact that each individual’s
exposure has been assessed separately, with
good analytical accuracy. Any analytical impre-
cision would have caused a bias toward the null.
Urinary spot samples must be adjusted for
dilution. This is frequently done by adjusting
to urinary creatinine, but this method may
induce bias because it is dependent upon mus-
cle mass and thus affected by age and physical
ﬁtness (Suwazono et al. 2005), which are also
predictors of bone status. In fact, creatinine-
adjusted urinary cadmium displayed an even
more pronounced statistically signiﬁcant asso-
ciation with BMD. In view of this possible
bias, we chose to correct by density (Åkesson
et al. 2005; Suwazono et al. 2005). However,
the choice is not obvious, especially not in a
population as homogeneous for sex and age as
that examined in the present study.
The cross-sectional study design precludes
definite conclusions as to the direction of
causality. The bone markers also showed clear
associations with blood lead. Considering that
about 90% of all the body burden of lead is
localized to bone, even a minor increase of
skeletal turnover, as in menopause, would
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Figure 1. Association between forearm BMD and
urinary cadmium (U-Cd) adjusted to density.
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Figure 2. Association between U-DPD and urinary
cadmium (U-Cd) adjusted to density.
Table 2. Associations between exposure and bone-related variables (Spearman rank correlation coefﬁcients).
Blood Urinary Blood Pack-years Urinary
cadmium cadmium lead Menarche of smoking Alcohol Weight BMD PTH Osteocalcin bALP U-DPD calcium
Age –0.02 –0.03 –0.04 0.09* –0.07† –0.15** 0.06† –0.18** 0.03 0.06 0.08* –0.02 –0.04
Menarche 0.05 0.04 0.08*
Pack-years 0.57** 0.41** 0.19** 0
of smoking
Alcohol –0.01 0.02 0.36** 0.02 0.10*
Weight –0.11* –0.15** –0.07† –0.12** –0.07* –0.08*
BMD –0.08* –0.12** –0.07† –0.07* –0.04 0.01 0.35**
PTH –0.10* –0.17** –0.06 NR –0.10* –0.12** 0.11* 0
Osteocalcin –0.03 0.05 0.23** NR –0.08* –0.13** –0.08* –0.24** 0.17**
bALP 0.02 0.08* 0.17** NR 0.05 –0.09* 0.09* –0.20** 0.16** 0.56**
U-DPD 0.07† 0.27** 0.11* NR 0.04 –0.07* 0.05 –0.05 –0.06 0.25** 0.23**
Urinary calcium –0.02 0.01 0.12* NR –0.01 0.03 –0.03 –0.12** –0.11* 0.17** 0.16** 0.02
NR, not relevant. 
†0.05 < p ≤ 0.10. *0.001 < p ≤ 0.05. **p ≤ 0.001.affect the levels of lead in blood. Interestingly,
the inclusion of HRT in the models decreased
the strength of these associations, which indi-
cates an effect of menopause and a protective
effect of estrogen therapy, as previously shown
(Garrido Latorre et al. 2003; Korrick et al.
2002; Nash et al. 2004; Vahter et al. 2004;
Webber et al. 1995). Because the skeleton
contains only minor amounts of cadmium
(Petersson Grawe and Oskarsson 2000), it
seems highly unlikely that an increased bone
turnover would release signiﬁcant amounts of
cadmium.
This is the first study on cadmium-
associated effects on bone in a population
residing in an area with no known historical
cadmium contamination, assuming a rather
constant exposure over time. Nevertheless,
our results are in accordance with ﬁndings of
cadmium-associated effects on BMD and
fractures in Swedes (of both sexes) with a sim-
ilarly low present environmental exposure
(Alfvén et al. 2000, 2004), Belgians with a
somewhat higher exposure (Staessen et al.
1999), Japanese women (Honda et al. 2003),
and Chinese men and women (Nordberg et al.
2002; Wang et al. 2003) with considerably
higher exposure levels. In the present study,
we obtained detailed information on several
possible risk modifiers and confounders for
osteoporosis, such as physical activity, menar-
che, menopausal status, and HRT. This
enabled us to ascertain associations between
low cadmium exposure and bone effects and
our findings support a causal explanation.
The effect of cadmium on bone resorption in
our study was even more pronounced after
menopause (interaction), in accordance with
results from animal (Bhattacharyya et al.
1988) and human studies (Staessen et al.
1999), and in line with the fact that those
affected by the Itai-itai disease were mainly
women after menopause (Kjellström 1986).
Although the mechanism by which cad-
mium exerts effects on bone is far from clear,
studies on humans have indicated an effect
mediated through kidney damage (Alfvén et al.
2000; Horiguchi e al. 2005; Nordberg et al.
2002). We explored the mechanism by meas-
uring markers of both bone metabolism and
kidney effects. In contrast to previous reports,
we suggest a direct effect of cadmium on bone
resorption (osteoclasts), resulting in increased
U-DPD. Such stimulation of bone resorption
has been demonstrated in both animal and
in vitro studies (Bhattacharyya et al. 1988;
Brzoska and Moniuszko-Jakoniuk 2004, 2005;
Carlsson and Lundholm 1996; Regunathan
et al. 2003; Sacco-Gibson et al. 1992; Wilson
et al. 1996). Because PTH is the main regulator
of calcium metabolism, an increased bone
resorption would lead to a compensatory
decrease in PTH, which is in line with our
results. The fact that we found no association
between cadmium and bone formation (osteo-
calcin and bALP) may reflect a cadmium-
induced uncoupling between bone resorption
and formation (Uriu et al. 2000). In contrast,
studies on patients with Itai-itai showed
increased levels of markers of bone formation
compared with controls (Aoshima et al. 2003;
Kido et al. 1991; Tsuritani et al. 1994), and
studies of other subjects with cadmium-
induced tubular damage showed increased
PTH (Nogawa et al. 1984; Tsuritani et al.
1992). This may indicate other mechanisms are
involved in subjects with severe kidney damage.
An indirect effect on bone due to cad-
mium-induced kidney damage (Alfvén et al.
2000; Kjellström 1992), via impaired activa-
tion of vitamin D (Kjellström 1992; Nogawa
et al. 1987), and increased excretion of cal-
cium and decreased bone formation has been
proposed. However, we found no association
between cadmium and urinary calcium
(Åkesson et al. 2005) or markers of bone for-
mation (osteocalcin and bALP). This would
indicate that the kidney was not involved,
although the associations between the effect
on bone and some of the renal effect markers
may indicate some kidney-mediated effect.
Even though radius BMD is likely to
reﬂect the risk of forearm fractures, it may not
be a good index of osteoporosis in other parts
of the skeleton, although there was correla-
tion, albeit weak, between BMD of the radius
and the hip in 81 women of the WHILA
cohort (data not shown). Evaluation of cad-
mium exposure in relation to BMD of other
sites associated with increased fracture risk,
such as hip and lumbar spine, is required.
Clearly, the overall role of cadmium in
the etiology of osteoporosis is limited. The
observed difference in BMD between high-
and low-exposed individuals corresponded
to that of a 6-year increase in age or an
11-kg lower body weight. However, in view
of the high prevalence of this disease, even a
minor contribution is important at the pop-
ulation level. Furthermore, because the main
cadmium exposure is via foods considered
healthful and because everyone has lifelong
exposure, our findings in combination with
the observed effects on kidney (Åkesson
et al. 2005) emphasize the importance of
activities to reduce cadmium pollution of
the environment.
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Figure 3. Association between blood lead (B-Pb)
and serum osteocalcin.
Table 3. Multiple linear regression models between bone-related markers and either urinary or blood cadmium.
Urinary cadmium Blood cadmium
Dependent/independent variable β 95% CI R2 β 95% CI R2
BMD (g/cm2)
Cadmium (µg/L)a –0.011 –0.022 to –0.0002 0.24 –0.002 –0.009 to 0.006 0.22
Weight (kg) 0.002 0.002 to 0.002 0.002 0.002 to 0.003
Age (years) –0.004 –0.006 to –0.003 –0.004 –0.006 to –0.003
Menopauseb p < 0.001 p < 0.001
Seasonb p = 0.018 NS
Menarche NS NS
PTH (ng/L)
Cadmium (µg/L)a –4.3 –7.1 to –1.5 0.10 –2.2 –4.0 to –0.37 0.09
Weight (kg) 0.14 0.06 to 0.22 0.15 0.07 to 0.23
Alcohol (g/week) –0.03 –0.05 to –0.01 –0.03 –0.05 to –0.006
Seasonb p < 0.001 p < 0.001
Pack-years NS NS
bALP (µg/L)
Cadmium (µg/L)a 0.95 –0.04 to 1.9 0.14
Menopauseb p < 0.001
Alcohol (g/week) NS
Weight (kg) NS
Age NS
U-DPD (nmol/L)
Cadmium (µg/L)a,* 17 14 to 21 0.12 1.8 –0.7 to 4.4 0.03
Menopauseb p < 0.001 p < 0.001
Seasonb NS NS
Alcohol (g/week) NS NS
Abbreviations: CI, conﬁdence interval; NS, not signiﬁcant; R2, explained adjusted variance for the total model.
aAdjusted to the mean urinary density. bThree categories for menopause (HRT, premenopause, and postmenopause) and
three categories for season (summer, fall, and winter) were included in the models as fixed factors (β not estimated).
*Signiﬁcant interactions: urinary cadmium and menopause (p = 0.022).Åkesson et al.
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